Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient's IADL?
Quirien OortLinda DirvenSietske A M SikkesNeil AaronsonFlorien W BoeleChristine BrannanJonas EgeterRobin GrantMartin KleinIrene M LipsYoshitaka NaritaHitomi SatoMonika SztankayGünther StockhammerAndrea TalacchiBernard M J UitdehaagJaap C ReijneveldMartin J B TaphoornPublished in: Neuro-oncology practice (2022)
Neurocognitive deficits seem to play a role in the discrepancies between brain tumor patients and their proxies assessment of patient's level of IADL. Although replication of our results is needed, our findings suggests that caution is warranted in interpreting self-reported IADL by patients with neurocognitive impairment, and that such self-reports should be supplemented with proxy ratings.